GlobeNewswire·Feb 25, 2026, 7:30 AM ET

Medline Reports Fourth Quarter and Full Year 2025 Results

Medline Inc. delivered strong full-year 2025 results & completed its Initial Public Offering (IPO).
Fourth quarter 2025 net sales reached $7.8 billion, an increase of 14.8% year-over-year.
Fourth quarter 2025 net income was $180 million, a decrease of 37.7% due to tariffs, higher operating costs, & IPO-related expenses.
Fourth quarter 2025 Adjusted EBITDA was $805 million, approximately flat compared to the prior year.
Full-year 2025 net sales totaled $28.4 billion, an increase of 11.5% driven by increased volumes in Medline Brand & Supply Chain Solutions segments.
Full-year 2025 net income was $1.2 billion, a decrease of 3.6% primarily due to higher costs of goods sold from tariffs & operating costs.
Full-year 2025 Adjusted EBITDA was $3.5 billion, an increase of 3.2%.
The company recorded $2.4 billion in total new customer signings during 2025.
Full-year 2025 net cash provided by operating activities was $1.7 billion.
Full-year 2025 Free Cash Flow was $1.3 billion, offset by capital expenditures for distribution center enhancements & kitting manufacturing investments.
Medline introduced full-year 2026 guidance expecting Organic Sales growth of 8% to 9% & Adjusted EBITDA of $3.5 billion to $3.6 billion.
A conference call to discuss results was held on February 25, 2026, at 8:30 a.m. CT / 9:30 a.m. ET.